PATH vs PMCB
Uipath Inc (PATH) versus PharmaCyte Biotech Inc (PMCB) — a side-by-side from cached financials, not a winner call.
Uipath Inc (PATH) is a software - infrastructure company listed on US.
PharmaCyte Biotech Inc (PMCB) is a biotechnology company listed on NASDAQ.
Latest reported PATH revenue for 2026-01-31 was $1.61B. Net income was $282.3M. Revenue was up 12.7% from 2025-01-31 to 2026-01-31. PATH currently screens at market cap $6.07B and trailing P/E 19.4.
Latest reported PMCB revenue for 2025-04-30 was $0. Net income was $30.7M. PMCB currently screens at market cap $8.6M.
PATH currently screens at market cap $6.07B and trailing P/E 19.4. PMCB currently screens at market cap $8.6M.
Not investment advice. Open the PATH and PMCB stock pages for the full models.
Not investment advice.